The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $64.84

Today's change-0.50 -0.77%
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.
 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $64.84

Today's change-0.50 -0.77%
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.

Bristol-Myers Squibb Co down (U.S.)$0.50

Bristol-Myers Squibb Co closed lower Tuesday, dropping (U.S.)$0.50 or 0.77% to (U.S.)$64.84. Over the last five days, shares have gained 0.28% and 9.84% year to date. Shares have outperformed the S&P 500 by 21.77% during the last year.

Key company metrics

  • Open(U.S.) $65.47
  • Previous close(U.S.) $65.34
  • High(U.S.) $65.55
  • Low(U.S.) $64.65
  • Bid / Ask-- / --
  • YTD % change+9.84%
  • Volume3,890,142
  • Average volume (10-day)6,755,043
  • Average volume (1-month)5,788,678
  • Average volume (3-month)6,652,445
  • 52-week range(U.S.) $47.55 to (U.S.) $70.54
  • Beta0.28
  • Trailing P/E60.65×
  • P/E 1 year forward35.60×
  • Forward PEG1.87×
  • Indicated annual dividend(U.S.) $1.48
  • Dividend yield2.28%
  • Trailing EPS(U.S.) $1.07
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.16%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue4,1634,0414,2583,921
Total other revenue--------
Total revenue4,1634,0414,2583,921
Gross profit3,1753,2283,3232,950
Total cost of revenue988813935971
Total operating expense4,1182,7524,3183,210
Selling / general / administrative1,1351,0291,3641,200
Research & development9851,0161,139918
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)1,14498927192
Other operating expenses, total-134-204-47-71
Operating income451,289-60711
Interest income (expense), net non-operating-49-51-53-50
Gain (loss) on sale of assets8154-3315
Other--------
Income before tax521,448-601,008
Income after tax-1101,19927732
Income tax, total162249-87276
Net income-1301,18613721
Total adjustments to net income--------
Net income before extra. items-1301,18613721
Minority interest-20-13-14-11
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1301,18613721
Inc. avail. to common incl. extra. items-1301,18613721
Diluted net income-1301,18613721
Dilution adjustment--------
Diluted weighted average shares1,6671,6761,6761,670
Diluted EPS excluding extraordinary itemsvalue per share-0.080.710.010.43
Dividends per sharevalue per share0.370.370.370.36
Diluted normalized EPSvalue per share0.430.660.380.35